Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05707273 · ClinicalTrials.gov registry record · Phase 1

CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission

A Phase 1 study of B Acute Lymphoblastic Leukemia, sponsored by City of Hope Medical Center.

Active
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT05707273 is a Phase 1 study of B Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 18 participants, below the 1,026-participant average among 20 other B Acute Lymphoblastic Leukemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05707273, a Phase 1 study of B Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by City of Hope Medical Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of B-cell acute lymphoblastic leukemia.

Conditions Studied

B Acute Lymphoblastic Leukemia

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Marrow Aspiration and Biopsy
  • DRUG Autologous Anti-CD19 CAR-expressing T Lymphocytes

Study Locations (1)

California

  • City of Hope Medical Center - Duarte

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2023-04-26
Est. Completion 2026-07-24
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05707273

The ClinicalTrials.gov registry entry for NCT05707273 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,026-participant average among 20 other B Acute Lymphoblastic Leukemia trials with a reported enrollment target (98% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT05707273 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05707273 about?

NCT05707273 is a clinical study titled "CD19-Car T Cell Therapy for the Treatment of Older Adults With Acute Lymphoblastic Leukemia in First Remission". This phase I trial tests the safety, side effects, and best dose of autologous anti-CD19 CAR-expressing T lymphocytes (CD19-CAR T cells) in older adults with B-cell acute lymphoblastic leukemia. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a typ...

What is the current status of trial NCT05707273?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-04-26. Estimated completion is 2026-07-24.

What conditions does trial NCT05707273 study?

This clinical trial studies the following conditions: B Acute Lymphoblastic Leukemia.

What interventions are being tested in trial NCT05707273?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Biospecimen Collection (PROCEDURE), Bone Marrow Aspiration and Biopsy (PROCEDURE), Autologous Anti-CD19 CAR-expressing T Lymphocytes (DRUG).

Who is sponsoring clinical trial NCT05707273?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05707273 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B Acute Lymphoblastic Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.